Table 2. Association between D-dimer levels and clinicopathological features in patients with endometrial cancer (n=176).
| Influencing factor | Subgroup | Pre-operative | 1st post-operative day | |||||
|---|---|---|---|---|---|---|---|---|
| D-dimer <0.55 mg/L | D-dimer ≥0.55 mg/L | P value | D-dimer <0.55 mg/L | D-dimer ≥0.55 mg/L | P value | |||
| Age (Y) | <60 | 99 (84.6%) | 18 (15.4%) | 0.274 | 30 (25.6%) | 87 (74.4%) | 0.016* | |
| ≥60 | 46 (78%) | 13 (22%) | 6 (10.2%) | 53 (89.8%) | ||||
| Body mass index (BMI) (kg/m2) | <25 | 83 (83.8%) | 16 (16.2%) | 0.431 | 17 (17.2%) | 82 (82.8%) | 0.221 | |
| ≥25 | 61 (79.2%) | 15 (20.8%) | 19 (24.7%) | 58 (75.3%) | ||||
| FIGO stage | I–II | 122 (83%) | 25 (27%) | 0.634 | 36 (24.5%) | 111 (75.5%) | 0.001* | |
| III–IV | 23 (79.3%) | 6 (20.7%) | 0 (0%) | 29 (100%) | ||||
| Tumor differentiation | G1 | 108 (80%) | 27 (20%) | 0.097 | 34 (25.2%) | 101 (74.8%) | 0.002* | |
| G2–3 | 37 (90.2%) | 4 (9.8%) | 2 (4.9%) | 39 (95.1%) | ||||
| Myometrial infiltration | <1/2 | 119 (81.5%) | 27 (18.5%) | 0.352 | 35 (24%) | 111 (76%) | 0.05* | |
| ≥1/2 | 26 (86.7%) | 4 (13.3%) | 1 (3.3%) | 29 (96.7%) | ||||
| Cervical stromal invasion | Negative | 129 (82.7%) | 27 (17.3%) | 0.484 | 35 (22.4%) | 121 (77.6%) | 0.053 | |
| Positive | 16 (80%) | 4 (20%) | 1 (5%) | 19 (95%) | ||||
| Lymphovascular space invasion | Negative | 127 (81.4%) | 29 (18.6%) | 0.274 | 35 (22.4%) | 121 (77.6%) | 0.053 | |
| Positive | 18 (90%) | 2 (10%) | 1 (5%) | 19 (95%) | ||||
| Lymph node metastasis | Negative | 140 (82.8%) | 29 (17.2%) | 0.357 | 36 (21.3%) | 133 (78.7%) | 0.195 | |
| Positive | 5 (71.4%) | 2 (28.6%) | 0 (0%) | 7 (100%) | ||||
| VTE | Negative | 137 (83%) | 28 (17%) | 0.385 | 36 (21.8%) | 129 (78.2%) | 0.074 | |
| Positive | 8 (72.7%) | 3 (27.3%) | 0 (0%) | 11 (100%) | ||||
| CA125 (U/mL) | <35 | 122 (84.1%) | 23 (15.9%) | 0.187 | 32 (22.1%) | 113 (77.9%) | 0.185 | |
| ≥35 | 23 (74.2%) | 8 (25.8%) | 4 (12.9%) | 27 (87.1%) | ||||
| Pathological type | Type I | 129 (81.6%) | 29 (18.4%) | 0.445 | 35 (22.2%) | 123 (77.8%) | 0.08 | |
| Type II | 16 (88.9%) | 2 (11.1%) | 1 (5.6%) | 17 (94.4%) | ||||
| Platelet count (×109/L) | <320 | 126 (84.6%) | 23 (15.4%) | 0.027 | 32 (21.5%) | 117 (78.5%) | 0.308 | |
| ≥320 | 18 (66.7%) | 9 (33.3%) | 4 (14.8%) | 23 (85.2%) | ||||
| MS | MSS | 120 (84.5%) | 22 (15.5%) | 0.131 | 31 (21.8%) | 111 (78.2%) | 0.355 | |
| MSI | 25 (73.5%) | 9 (26.5%) | 5 (14.7%) | 29 (85.3%) | ||||
VTE, venous thromboembolism.